Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis
Janki Patel, Ricki Bettencourt, Jeffrey Cui, et al.
Therapeutic Advances in Gastroenterology (2016) Vol. 9, Iss. 5, pp. 692-701
Open Access | Times Cited: 142

Showing 1-25 of 142 citing articles:

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
Laurent Castéra, Mireen Friedrich‐Rust, Rohit Loomba
Gastroenterology (2019) Vol. 156, Iss. 5, pp. 1264-1281.e4
Open Access | Times Cited: 1172
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1137
Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease
Charlie C. Park, Phirum Nguyen, Carolyn Hernandez, et al.
Gastroenterology (2016) Vol. 152, Iss. 3, pp. 598-607.e2
Open Access | Times Cited: 599
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy, et al.
The Lancet (2019) Vol. 394, Iss. 10213, pp. 2012-2024
Closed Access | Times Cited: 574
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra, et al.
Diabetes Care (2018) Vol. 41, Iss. 8, pp. 1801-1808
Open Access | Times Cited: 496
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Arun J. Sanyal, Edgar D. Charles, Brent A. Neuschwander‐Tetri, et al.
The Lancet (2018) Vol. 392, Iss. 10165, pp. 2705-2717
Closed Access | Times Cited: 460
Noninvasive, Quantitative Assessment of Liver Fat by MRI‐PDFF as an Endpoint in NASH Trials
Cyrielle Caussy, Scott B. Reeder, Claude B. Sirlin, et al.
Hepatology (2018) Vol. 68, Iss. 2, pp. 763-772
Open Access | Times Cited: 402
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison, Mary E. Rinella, Manal F. Abdelmalek, et al.
The Lancet (2018) Vol. 391, Iss. 10126, pp. 1174-1185
Closed Access | Times Cited: 381
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 393-406
Closed Access | Times Cited: 317
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Rohit Loomba, Zeid Kayali, Mazen Noureddin, et al.
Gastroenterology (2018) Vol. 155, Iss. 5, pp. 1463-1473.e6
Open Access | Times Cited: 291
Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis
Takeshi Yokoo, Suraj D. Serai, Ali Pirasteh, et al.
Radiology (2017) Vol. 286, Iss. 2, pp. 486-498
Open Access | Times Cited: 269
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel, Stephen A. Harrison, Magdy Elkhashab, et al.
Hepatology (2020) Vol. 72, Iss. 1, pp. 58-71
Closed Access | Times Cited: 266
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial
Samer Gawrieh, Mazen Noureddin, Nicole Loo, et al.
Hepatology (2021) Vol. 74, Iss. 4, pp. 1809-1824
Open Access | Times Cited: 260
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A. Harrison, Peter Ruane, B. Freilich, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1262-1271
Open Access | Times Cited: 252
Liver fat imaging—a clinical overview of ultrasound, CT, and MR imaging
Yingzhen Zhang, Kathryn J. Fowler, Gavin Hamilton, et al.
British Journal of Radiology (2018), pp. 20170959-20170959
Open Access | Times Cited: 244
Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis
Michael S. Middleton, Elhamy Heba, Catherine A. Hooker, et al.
Gastroenterology (2017) Vol. 153, Iss. 3, pp. 753-761
Open Access | Times Cited: 242
Limitations of non-invasive tests for assessment of liver fibrosis
Keyur Patel, Giada Sebastiani
JHEP Reports (2020) Vol. 2, Iss. 2, pp. 100067-100067
Open Access | Times Cited: 228
Noninvasive Diagnosis of NAFLD and NASH
Valeria Piazzolla, Alessandra Mangia
Cells (2020) Vol. 9, Iss. 4, pp. 1005-1005
Open Access | Times Cited: 204
Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys
Jeffrey B. Schwimmer, Patricia Ugalde‐Nicalo, Jean A. Welsh, et al.
JAMA (2019) Vol. 321, Iss. 3, pp. 256-256
Open Access | Times Cited: 203
Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis
Eric Lawitz, Angie Coste, Fred Poordad, et al.
Clinical Gastroenterology and Hepatology (2018) Vol. 16, Iss. 12, pp. 1983-1991.e3
Closed Access | Times Cited: 191
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib
Saumya Jayakumar, Michael S. Middleton, Eric Lawitz, et al.
Journal of Hepatology (2018) Vol. 70, Iss. 1, pp. 133-141
Open Access | Times Cited: 180
Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
Jonathan G. Stine, Nagambika Munaganuru, Abbey Barnard, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 11, pp. 2274-2283.e5
Open Access | Times Cited: 166
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Roberto A. Calle, Neeta B. Amin, Santos Carvajal‐Gonzalez, et al.
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1836-1848
Closed Access | Times Cited: 156
Quantification of Liver Fat Content with CT and MRI: State of the Art
Jitka Starekova, Diego Hernando, Perry J. Pickhardt, et al.
Radiology (2021) Vol. 301, Iss. 2, pp. 250-262
Open Access | Times Cited: 150
Management of non-alcoholic fatty liver disease
Maria Letizia Petroni, Lucia Brodosi, Elisabetta Bugianesi, et al.
BMJ (2021), pp. m4747-m4747
Open Access | Times Cited: 147
Page 1 - Next Page

Scroll to top